# Antares Therapeutics

> Antares Therapeutics is a Boston-based biotechnology company that discovers small-molecule precision medicines against historically 'undruggable' targets in cancer and other serious diseases. Spun out of Scorpion Therapeutics in June 2025 with $177 million in Series A financing, Antares combines proprietary compound libraries, next-generation mass spectrometry, chemical proteomics, and machine-learning-driven computational chemistry to find new binding pockets on proteins - such as transcription factors - that were long considered impossible to drug. Its lead program is slated to enter the clinic in 2026, and the company signed a collaboration worth up to $1.9 billion with Novartis in mid-2026.

- **Founded:** 2025
- **Headquarters:** Boston, Massachusetts, United States
- **Founders:** Adam Friedman (President & Chief Executive Officer)
- **Team size:** ~160 employees
- **Products:** Antares Discovery Engine, Covalent & allosteric small-molecule programs
- **Notable:** Launched in June 2025 with a $177 million Series A - one of the larger biotech launch rounds of the year., Signed a collaboration with Novartis worth $105M upfront and up to ~$1.9 billion in total value within a year of launch., Assembled a leadership team and board of veteran oncology and drug-discovery figures.

## Products & services

- **Antares Discovery Engine** — An integrated small-molecule discovery platform built on three pillars - medicinal chemistry (proprietary compound libraries and next-generation mass spectrometry to find new chemical pockets), target biology (human genetics and functional genomics for target validation), and predictive sciences (physics-based modeling, molecular dynamics, and machine learning).
- **Covalent & allosteric small-molecule programs** — A preclinical pipeline of first-in-class small molecules aimed at undruggable oncology targets, including transcription factors, with the most advanced program expected to enter clinical testing in 2026.

## Achievements

- Launched in June 2025 with a $177 million Series A - one of the larger biotech launch rounds of the year.
- Signed a collaboration with Novartis worth $105M upfront and up to ~$1.9 billion in total value within a year of launch.
- Assembled a leadership team and board of veteran oncology and drug-discovery figures.
- Advanced a preclinical pipeline toward a first clinical candidate expected in 2026.

## Latest updates

- **2026-06** — Antares entered a collaboration with Novartis to discover and develop first-in-class cancer therapies against undruggable targets - $105M upfront, up to ~$1.9B total, plus tiered royalties.
- **2025-06** — Company launched publicly with $177M Series A financing as a spin-out of Scorpion Therapeutics.

## Links

- Website: https://antaresrx.com
- LinkedIn: https://www.linkedin.com/company/antares-therapeutics
- Twitter/X: https://twitter.com/antares_rx
- Instagram: https://www.instagram.com/antares_rx

---

Profile page: https://yespress.io/antares-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-22